568 related articles for article (PubMed ID: 16265708)
1. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G; Masi L; Giani T; Piscitelli E; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2005 Nov; 32(11):2233-8. PubMed ID: 16265708
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
[TBL] [Abstract][Full Text] [Related]
3. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
4. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
Crisafulli A; Micari A; Altavilla D; Saporito F; Sardella A; Passaniti M; Raffa S; D'anneo G; Lucà F; Mioni C; Arrigo F; Squadrito F
Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884
[TBL] [Abstract][Full Text] [Related]
6. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
7. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
8. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
[TBL] [Abstract][Full Text] [Related]
10. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
Gannagé-Yared MH; Fares F; Semaan M; Khalife S; Jambart S
Clin Endocrinol (Oxf); 2006 Jun; 64(6):652-8. PubMed ID: 16712667
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin levels in healthy controls and cancer patients.
Lipton A; Ali SM; Leitzel K; Chinchilli V; Witters L; Engle L; Holloway D; Bekker P; Dunstan CR
Clin Cancer Res; 2002 Jul; 8(7):2306-10. PubMed ID: 12114435
[TBL] [Abstract][Full Text] [Related]
13. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
15. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
18. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
[TBL] [Abstract][Full Text] [Related]
19. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[TBL] [Abstract][Full Text] [Related]
20. [Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease].
Peng Q; Wu Q; Chen CH; Hong H; Zhang LY
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Jun; 8(3):208-10. PubMed ID: 16787593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
